Margarida Maia, PhD,  science writer—

Sionna Therapeutics has gained the rights to develop and market three of AbbVie’s clinical-stage compounds, a move that expands the company’s pipeline of small molecules that are designed to restore the function of the CFTR protein, which is faulty or absent in cystic fibrosis (CF). The compounds…

Despite treatment with Kalydeco (ivacaftor), females with cystic fibrosis (CF) continue to experience more lung exacerbations — periods when CF respiratory symptoms suddenly worsen — than do males, for reasons that are not well understood, a large patient registry study reported. “Our findings demonstrate that sex disparities…

Despite recent guidelines recommending nutrient consumption similar to the general population, many adults and late adolescents with cystic fibrosis (CF) still follow a high-fat, high-energy diet, according to a review done by researchers in Australia. The findings suggest that “overall, diet intakes of adults with CF appear to be…

Tezacaftor, a medication used to treat cystic fibrosis (CF), may unexpectedly trap certain fats in the lungs, diverting their use as chemical raw material that the body converts into ceramides, which are needed for the brain to develop and respond to stress, according to…

Children with cystic fibrosis (CF) who are being treated with Symdeko (ivacaftor/tezacaftor) or Orkambi (ivacaftor/lumacaftor) experience few to no symptoms of chronic rhinosinusitis and maintain a normal sense of smell, a study in Denmark found. Although small, the study suggests that not only Trikafta, a triple…

CFTR modulators may help control glucose (sugar) levels in the blood of people with cystic fibrosis (CF), according to researchers in Israel, who called for regular oral glucose tolerance testing to adjust insulin dosing in diabetes and keep glucose from dropping too low. The study, “Long-Term therapy with…

Low doses of ETD001, an inhaled medication being develop by Enterprise Therapeutics to treat cystic fibrosis (CF), acted for longer than expected and helped to clear mucus from the airways of sheep in a study. Equivalent doses also were well tolerated in an earlier Phase…

ARCT-032, a messenger RNA inhalation treatment being developed by Arcturus Therapeutics to restore a working protein in the lungs of cystic fibrosis (CF) patients, showed safety in healthy adults and early signs of potential efficacy in a small group of patients taking part in a Phase 1/1b…

Women with cystic fibrosis (CF) who have been pregnant three or more times are more likely to experience a greater decline in lung function and, when 30 or older, to give birth to preterm babies or babies with complications, a study has found. Lung function appeared to decline more…

Certain neutrophils, a type of immune cell that’s released quickly into the bloodstream to help fight off infections, appear to be linked to better lung function in some people with cystic fibrosis (CF), a study finds. The presence or abundance in the blood of certain other immune cells and…